Large Molecule Bioanalytical Technologies Market Size, Share & Trends Analysis Report By Products & Services, By Application (Biologics, Oligonucleotide Derived Drugs & Molecules), By Region, And Segment Forecasts, 2025 - 2030

Market Size & Trends

The global large molecule bioanalytical technologies market size was valued at USD 9.29 billion in 2024 and is expected to grow at a CAGR of 10.2% from 2025 to 2030. This growth can be attributed to the increasing incidence of chronic diseases, such as cancer, diabetes, and cardiovascular conditions, and the rising demand for biopharmaceuticals. Biopharmaceuticals, including monoclonal antibodies, vaccines, and gene therapies, require precise and advanced testing methods to ensure their safety, efficacy, and quality.

The increasing global demand for biologic drugs is driving the need for advanced bioanalytical technologies to analyze large molecules, which in turn fuels market growth and supports the development of new therapeutic solutions. Along with the ongoing shift toward R&D programs for large molecules, the increasing diversity in the therapeutic modalities being tested analytically is evident. This trend demands broader expertise to assess final product quality attributes, driving the market for large molecule bioanalytical technologies. Furthermore, regulatory pressure plays a crucial role in prompting a more detailed analysis of final products. These innovative drugs require a thorough biocompatibility, toxicology, and chemical characterization assessment to ensure efficacy and safety for human consumption. The integration of biochemical testing with digital technologies presents both opportunities and challenges for analytical testing laboratories.

The shift toward personalized medicine, coupled with advances in biotechnology and biomanufacturing, is anticipated to accelerate the large molecule bioanalytical technologies industry. Personalized medicine aims to tailor treatments to individual genetic profiles, increasing the demand for precise bioanalytical tools to support drug development and monitoring. In addition, breakthroughs in biotechnology and biomanufacturing enhance the production and scaling of biologic drugs, necessitating advanced analytical techniques for quality control, efficacy testing, and regulatory compliance, fueling market expansion.

Products & Services Insights

The product segment dominated the market with the largest revenue share of 71.5% in 2024, propelled by the growing demand for advanced tools and instruments used in the analysis of biologics. These products, including analytical instruments, reagents, and consumables, are essential for assessing the quality, stability, and efficacy of large molecule drugs. As the biopharmaceutical industry expands, driven by the increasing focus on biologics and personalized medicine, the need for reliable and precise bioanalytical solutions continues to rise, reinforcing the dominance of the product segment in the market.

The services segment is anticipated to emerge as the fastest-growing segment at a CAGR of 10.8% from 2025 to 2030, owing tothe increasing complexity of biologics and the rising demand for specialized testing. With advancements in biologics development, services such as analytical testing, validation, and regulatory support are becoming crucial for ensuring safety, efficacy, and compliance. The growing focus of pharmaceutical and biotech companies on biologics will drive the outsourcing of services to specialized providers, enabling streamlined operations, cost reduction, and access to advanced expertise. This trend is expected to further propel the growth of the services segment within the large molecule bioanalytical technologies industry.

Application Insights

The biologics segment secured the largest revenue share in 2024 due to the rapid growth of biologics, including monoclonal antibodies, gene therapies, and biosimilars. These complex molecules require highly specialized analytical techniques for development, testing, and quality control, driving demand for advanced bioanalytical technologies. The increasing approval of biologics for a wide range of diseases, particularly oncology and autoimmune disorders, has further fueled this growth. As the biologics pipeline expands, the need for precise, reliable testing methods continues to dominate the large molecule bioanalytical technologies industry.

The cell and gene therapy segment is expected to grow at the fastest CAGR during the forecast period. The increasing demand for personalized medicine and advanced treatments for genetic disorders drives the need for specialized bioanalytical tools. Technologies such as gene sequencing, cell-based assays, and advanced molecular diagnostics are crucial for ensuring the safety and efficacy of these therapies. Ongoing innovations in bioanalysis will support the development and commercialization of cell and gene therapies, positioning this segment for substantial growth in the market.

Regional Insights

North America large molecule bioanalytical technologies market held the largest revenue share of 34.2% in 2024, driven by the rising trend of regenerative medicine and the growing focus on cancer and rare diseases. As regenerative therapies, including stem cell treatments, gain momentum, the need for advanced bioanalytical tools is increasing to ensure the safety, potency, and quality of these innovative therapies. Moreover, biologic treatments for cancer and rare diseases demand precise bioanalytical testing to meet regulatory standards and optimize therapeutic efficacy, fueling regional market expansion.

U.S. Large Molecule Bioanalytical Technologies Market Trends

The U.S. large molecule bioanalytical technologies market held the largest share in 2024. The growing development and approval of biopharmaceuticals and a heightened focus on immunoassays are shaping the U.S. large molecule bioanalytical technologies industry. The expansion of the biopharmaceutical sector, particularly in biologics and monoclonal antibodies, drives the need for precise bioanalytical tools to ensure safety, efficacy, and quality. Immunoassays play a crucial role in evaluating the potency and structure of large molecules, fueling demand for advanced technologies that can meet the rigorous testing requirements of these complex therapeutics.

Europe Large Molecule Bioanalytical Technologies Market Trends

Europe large molecule bioanalytical technologies market is projected to record significant growth during the forecast period. The growth of biologics and biosimilars, coupled with the rising adoption of automated systems and digital platforms in bioanalysis, is set to propel the market. The increasing use of biologic therapies is impelling the demand for advanced, precise analytical tools to ensure their quality, efficacy, and regulatory compliance. Automation and digital platforms improve efficiency, accuracy, and data management, addressing the rising demand for high-throughput testing and faster drug development. These innovations fuel market growth by enhancing the scalability and reliability of bioanalytical processes in Europe. In September 2024, Thermo Fisher Scientific's PPD clinical research division announced the expansion of its bioanalytical laboratory services with a new facility in GoCo Health Innovation City, Gothenburg, Sweden. This lab will provide advanced services and cutting-edge instrumentation to support pharmaceutical and biotech clients throughout all phases of drug development.

Asia Pacific Large Molecule Bioanalytical Technologies Market Trends

APAC large molecule bioanalytical technologies market is anticipated to be the fastest-growing region with a CAGR of 11.7% from 2025 to 2030, propelled by the adoption of oligonucleotide therapies and the expansion of biomanufacturing. Oligonucleotide-based therapies, such as RNA and gene-editing treatments, require specialized bioanalytical technologies for precise analysis and quality control. The expansion of biomanufacturing capabilities in the region drives the demand for advanced tools to ensure consistent production and regulatory compliance of biologic drugs. This growth in therapeutic innovation and manufacturing infrastructure is fueling the demand for sophisticated bioanalytical solutions in Asia Pacific.

China large molecule bioanalytical technologies market is set to experience the fastest CAGR during the forecast period, driven by government support for biotechnology and the rise in personalized medicine. The Chinese government is heavily investing in biotechnology initiatives, promoting research and development in biologics, which increases the demand for advanced bioanalytical testing. Moreover, the growing focus on personalized medicine, which tailors treatments based on genetic profiles, impels the need for precise bioanalytical technologies to ensure efficacy and safety. Hence, a combination of governmental backing and demand for customized therapies propels the Chinese market growth.

Key Large Molecule Bioanalytical Technologies Company Insights

Some of the key companies in the large molecule bioanalytical technologies industry includeLabcorp; Merck KGaA; Charles River Laboratories; F. Hoffmann-La Roche Ltd; and Bio-Rad Laboratories, Inc.

• F. Hoffmann-La Roche Ltd provides innovative healthcare solutions, including pharmaceuticals, diagnostics, and biotechnology products. The company specializes in oncology, immunology, infectious diseases, and neuroscience, offering cutting-edge treatments and diagnostic tools to improve patient outcomes.

• Bio-Rad Laboratories, Inc. offers a broad range of life science research and clinical diagnostic products. These include instruments, reagents, and software for applications in genomics, proteomics, cell biology, and diagnostics across various research and healthcare fields.

Recent Developments

• In November 2023, Halo Labs introduced 0.8µm black membrane plates for Fluorescence Membrane Microscopy (FMM), aimed at helping large molecule drug developers analyze particles in highly concentrated, viscous solutions. This new addition enhanced their consumables offerings for particle characterization.

• In February 2023, Charles River Laboratories launched its first IgY-based ELISA kit for detecting and quantifying residual Host Cell Proteins (HCP) in CHO-based biotherapeutics. This novel tool enhances bioanalytical capabilities for evaluating biologic drug purity.

Large Molecule Bioanalytical Technologies Market Report Scope

Global Large Molecule Bioanalytical Technologies Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For the purpose of this study, Grand View Research has segmented the global large molecule bioanalytical technologies market report on the basis of products & services, application, and region:

• Products & Services Outlook (Revenue, USD Million, 2018 - 2030)

  • Product

    • Consumables & Accessories

    • Instruments

    • Reagents & Kits

  • Service

• Application Outlook (Revenue, USD Million, 2018 - 2030)

  • Biologics 

  • Oligonucleotide Derived Drugs & Molecules

  • Viral Vector

  • Cell & Gene Therapy

  • Nanoparticles & Polymers

• Regional Outlook (Revenue, USD Million, 2018 - 2030)

  • North America

    • U.S.

    • Canada

    • Mexico

  • Europe

    • UK

    • Germany

    • France

    • Italy

    • Spain

    • Denmark

    • Sweden

    • Norway

  • Asia Pacific

    • Japan

    • China

    • India

    • Australia

    • Thailand

    • South Korea

  • Latin America

    • Brazil

    • Argentina

  • Middle East & Africa

    • South Africa

    • Saudi Arabia

    • UAE

    • Kuwait